404 related articles for article (PubMed ID: 10820356)
1. Expression of the human mismatch repair gene hMSH2: a potential marker for urothelial malignancy.
Leach FS; Hsieh JT; Molberg K; Saboorian MH; McConnell JD; Sagalowsky AI
Cancer; 2000 May; 88(10):2333-41. PubMed ID: 10820356
[TBL] [Abstract][Full Text] [Related]
2. Human mismatch repair gene (hMSH2) product expression in relation to recurrence of transitional cell carcinoma of the urinary bladder.
Jin TX; Furihata M; Yamasaki I; Kamada M; Liang SB; Ohtsuki Y; Shuin T
Cancer; 1999 Jan; 85(2):478-84. PubMed ID: 10023718
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of microsatellite instability determined by immunohistochemical staining of hMSH2 and hMSH6 in urothelial carcinoma of the bladder.
Mylona E; Zarogiannos A; Nomikos A; Giannopoulou I; Nikolaou I; Zervas A; Nakopoulou L
APMIS; 2008 Jan; 116(1):59-65. PubMed ID: 18254781
[TBL] [Abstract][Full Text] [Related]
4. The mismatch repair gene hMSH2 is mutated in the prostate cancer cell line LNCaP.
Leach FS; Velasco A; Hsieh JT; Sagalowsky AI; McConnell JD
J Urol; 2000 Nov; 164(5):1830-3. PubMed ID: 11025778
[TBL] [Abstract][Full Text] [Related]
5. [Molecular changes in development and progression of urothelial carcinoma].
Hartmann A
Verh Dtsch Ges Pathol; 2003; 87():172-84. PubMed ID: 16888910
[TBL] [Abstract][Full Text] [Related]
6. [Expression of mismatch repair gene hMSH2 in human malignant ovarian tumors and its clinical significance].
Ma L; Zhang J; Peng Z
Zhonghua Fu Chan Ke Za Zhi; 2000 May; 35(5):291-3. PubMed ID: 11775911
[TBL] [Abstract][Full Text] [Related]
7. Detection of occult high graded microsatellite instabilities in MMR gene mutation negative HNPCC tumors by addition of complementary marker analysis.
Schiemann U; Müller-Koch Y; Gross M; Glas J; Baretton G; Muders M; Mussack T; Holinski-Feder E
Eur J Med Res; 2005 Jan; 10(1):23-8. PubMed ID: 15737950
[TBL] [Abstract][Full Text] [Related]
8. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H
Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669
[TBL] [Abstract][Full Text] [Related]
9. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction.
Christoph F; Müller M; Schostak M; Soong R; Tabiti K; Miller K
Urology; 2004 Jul; 64(1):157-61. PubMed ID: 15245962
[TBL] [Abstract][Full Text] [Related]
10. Expression of the human mismatch repair gene hMSH2 in normal and neoplastic tissues.
Leach FS; Polyak K; Burrell M; Johnson KA; Hill D; Dunlop MG; Wyllie AH; Peltomaki P; de la Chapelle A; Hamilton SR; Kinzler KW; Vogelstein B
Cancer Res; 1996 Jan; 56(2):235-40. PubMed ID: 8542572
[TBL] [Abstract][Full Text] [Related]
11. A novel germline mutation of MSH2 in a hereditary nonpolyposis colorectal cancer patient with liposarcoma.
Hirata K; Kanemitsu S; Nakayama Y; Nagata N; Itoh H; Ohnishi H; Ishikawa H; Furukawa Y;
Am J Gastroenterol; 2006 Jan; 101(1):193-6. PubMed ID: 16405554
[TBL] [Abstract][Full Text] [Related]
12. Value of reverse transcription polymerase chain assay in peripheral blood of patients with urothelial cancer.
Okegawa T; Kinjo M; Nutahara K; Higashihara E
J Urol; 2004 Apr; 171(4):1461-6. PubMed ID: 15017198
[TBL] [Abstract][Full Text] [Related]
13. Telomerase: a potential marker of bladder transitional cell carcinoma in bladder washes.
Lee DH; Yang SC; Hong SJ; Chung BH; Kim IY
Clin Cancer Res; 1998 Mar; 4(3):535-8. PubMed ID: 9533519
[TBL] [Abstract][Full Text] [Related]
14. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma.
Klein A; Zemer R; Buchumensky V; Klaper R; Nissenkorn I
Cancer; 1998 Jan; 82(2):349-54. PubMed ID: 9445193
[TBL] [Abstract][Full Text] [Related]
15. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer.
Prtilo A; Leach FS; Markwalder R; Kappeler A; Burkhard FC; Cecchini MG; Studer UE; Thalmann GN
J Urol; 2005 Nov; 174(5):1814-8; discussion 1818. PubMed ID: 16217293
[TBL] [Abstract][Full Text] [Related]
16. Genetic analysis of DNA microsatellite loci in salivary gland tumours: comparison with immunohistochemical detection of hMSH2 and p53 proteins.
Ohki K; Kumamoto H; Ichinohasama R; Suzuki M; Yamaguchi T; Echigo S; Motegi K; Ooya K
Int J Oral Maxillofac Surg; 2001 Dec; 30(6):538-44. PubMed ID: 11829237
[TBL] [Abstract][Full Text] [Related]
17. Low frequency of defective mismatch repair in a population-based series of upper urothelial carcinoma.
Ericson KM; Isinger AP; Isfoss BL; Nilbert MC
BMC Cancer; 2005 Mar; 5():23. PubMed ID: 15740628
[TBL] [Abstract][Full Text] [Related]
18. Expression of the mismatch repair protein hMSH2 in carcinoma in situ and invasive cancer of the breast.
Bock N; Meden H; Regenbrecht M; Jünemann B; Wangerin J; Marx D
Anticancer Res; 2000; 20(1A):119-24. PubMed ID: 10769643
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
20. P21-activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer.
Ito M; Nishiyama H; Kawanishi H; Matsui S; Guilford P; Reeve A; Ogawa O
J Urol; 2007 Sep; 178(3 Pt 1):1073-9. PubMed ID: 17644138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
